Intravenous gentamicin therapy induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients: An open label clinical trial

CONCLUSIONS: IV gentamicin induced readthrough of nonsense mutations in RDEB patients and restored functional C7 in their skin, enhanced wound healing, and improved clinical parameters. IV gentamicin may be a safe, efficacious, low cost, and readily available therapy in this population of RDEB patients.TRIAL REGISTRATION: Clinicaltrials.gov Identifiers: NCT03392909.PMID:38366625 | DOI:10.1093/bjd/ljae063

Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Authors: David T Woodley Michelle Hao Andrew Kwong Brandon Levian Jon Cogan Yingping Hou Daniel Mosallaei Elana Kleinman Kate Zheng Claire Chung Gene Kim David Peng Mei Chen Source Type: research